 The FDA has removed the clinical hold on uniQure NVs NASDAQ: QURE hemophilia B gene therapy program after determining the company had satisfactorily addressed all identified issues related to a single patient diagnosed with hepatocellular carcinoma HCC in the HOPE-B pivotal trial. Last month, a comprehensive investigation into the case of HCC diagnosed in one patient in the HOPE-B trial was concluded. 